A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Inclusion Criteria: * At least 18 years of age * Completely removed melanoma by surgery performed within 12 weeks of randomization * Advanced Melanoma * Tumor tissue from the resected site of the disease must be available for biomarker analyses in order to be randomized * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: * Previous anti-cancer treatment * Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug * Ocular or uveal melanoma or history of carcinomatosis meningitis * History of auto-immune disease * Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of the investigational product Other protocol-defined inclusion/exclusion criteria apply